2001-2006

This page in English

2006

Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.
Pincus T, Yazici Y, van Vollenhoven R
J. Rheumatol. 2006 Dec;33(12):2372-5

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al
Arthritis Rheum. 2006 May;54(5):1390-400

Rituximab-induced long-term remission of membranous lupus nephritis.
Jacobson S, van Vollenhoven R, Gunnarsson I
Nephrol. Dial. Transplant. 2006 Jun;21(6):1742-3

Swedish registers to examine drug safety and clinical issues in RA.
Askling J, Fored C, Geborek P, Jacobsson L, van Vollenhoven R, Feltelius N, et al
Ann. Rheum. Dis. 2006 Jun;65(6):707-12

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Breedveld F, Weisman M, Kavanaugh A, Cohen S, Pavelka K, van Vollenhoven R, et al
Arthritis Rheum. 2006 Jan;54(1):26-37

2005

In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al.
van Vollenhoven R, Gunnarsson I
Arthritis Rheum. 2005 Dec;52(12):4050-1; author reply 4051-2

Rheumatoid arthritis registries in Sweden.
van Vollenhoven R, Askling J
Clin. Exp. Rheumatol. ;23(5 Suppl 39):S195-200

Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Wick M, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven R
Scand. J. Rheumatol. ;34(5):353-8

Dehydroepiandrosterone versus placebo for Sjögren's syndrome: comment on the article by Pillemer et al.
van Vollenhoven R
Arthritis Rheum. 2005 Aug;53(4):626

Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression.
Rönnelid J, Wick M, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al
Ann. Rheum. Dis. 2005 Dec;64(12):1744-9

The treatment of rheumatoid arthritis: getting better all the time?
van Vollenhoven R, Klareskog L
Arthritis Rheum. 2005 Apr;52(4):991-4

Feasibility of 1 hour infliximab infusions.
van Vollenhoven R, Gullström E, Klareskog L
Ann. Rheum. Dis. 2005 Apr;64(4):654

Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis.
Wick M, Lindblad S, Weiss R, Klareskog L, van Vollenhoven R
Ann. Rheum. Dis. 2005 Jan;64(1):134-7

2004

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone.
van Vollenhoven R, Gunnarsson I, Welin-Henriksson E, Sundelin B, Osterborg A, Jacobson S, et al
Scand. J. Rheumatol. 2004 ;33(6):423-7

Clinical and radiological disease-course in a Swedish DMARD-treated early RA-inception cohort: an observational study.
Wick M, Lindblad S, Weiss R, Klareskog L, van Vollenhoven R
Scand. J. Rheumatol. 2004 ;33(6):380-4

B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies.
Bhat N, Bieber M, Yang Y, Leu Y, van Vollenhoven R, Teng N
Hum Antibodies 2004 ;13(3):63-8

"Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Reply"
van Vollenhoven R
Ann. Rev. Dis. 2004 May;63(5):608

Benefits and risks of biological agents: lymphomas.
van Vollenhoven R
Clin. Exp. Rheumatol. ;22(5 Suppl 35):S122-5

Switching between biological agents.
van Vollenhoven R
Clin. Exp. Rheumatol. ;22(5 Suppl 35):S115-21

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri M, Mease P, Merrill J, Lahita R, Iannini M, Yocum D, et al
Arthritis Rheum. 2004 Sep;50(9):2858-68

CD28nullCD4+ T cells--characterization of an effector memory T-cell population in patients with rheumatoid arthritis.
Fasth A, Cao D, van Vollenhoven R, Trollmo C, Malmström V
Scand. J. Immunol. ;60(1-2):199-208

CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease.
Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmström V
Arthritis Res. Ther. 2004 ;6(4):R335-46

CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease.
Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmström V
Arthritis Res. Ther. 2004 ;6(4):R335-46

Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description.
Wick M, Lindblad S, Klareskog L, Van Vollenhoven R
Ann. Rheum. Dis. 2004 Jul;63(7):848-52

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al
Ann. Rheum. Dis. 2004 Sep;63(9):1075-8

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.
van Vollenhoven R, Brannemark S, Klareskog L
Ann. Rheum. Dis. 2004 Apr;63(4):426-30

2003

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious.
van Vollenhoven R, Ernestam S, Harju A, Bratt J, Klareskog L
Arthritis Res. Ther. 2003 ;5(6):R347-51

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.
van Vollenhoven R, Harju A, Brannemark S, Klareskog L
Ann. Rheum. Dis. 2003 Dec;62(12):1195-8

Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.
van Vollenhoven R, Klareskog L
Arthritis Rheum. 2003 Jun;48(6):1500-3

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial.
Kavanaugh A, Genovese M, Baughman J, Kivitz A, Bulpitt K, Olsen N, et al
J. Rheumatol. 2003 Mar;30(3):449-54

2002

VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype.
Bhat N, Lee L, van Vollenhoven R, Teng N, Bieber M
J. Rheumatol. 2002 Oct;29(10):2114-21

Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri M, Lahita R, Van Vollenhoven R, Merrill J, Schiff M, Ginzler E, et al
Arthritis Rheum. 2002 Jul;46(7):1820-9

Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.
Gunnarsson I, Sundelin B, Heimbürger M, Forslid J, van Vollenhoven R, Lundberg I, et al
J. Rheumatol. 2002 Apr;29(4):693-9

Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.
van Vollenhoven R
Expert Opin Pharmacother 2002 Jan;3(1):23-31

2001

[Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
Larsson P, Bratt J, Harju A, van Vollenhoven R, Klareskog L
Lakartidningen 2001 Feb;98(8):828-31

Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus.
Svenungsson E, Andersson M, Brundin L, van Vollenhoven R, Khademi M, Tarkowski A, et al
Ann. Rheum. Dis. 2001 Apr;60(4):372-9

Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors.
Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L
Ann. Rheum. Dis. 2001 Feb;60(2):133-9

InflammationReumatologi